Clinical observation of nimotuzumab with chemotherapy in metastatic gastrointestinal tumor patients
10.3760/cma.j.issn.1006-9801.2012.07.007
- VernacularTitle:尼妥珠单抗联合化疗治疗晚期消化道肿瘤临床疗效观察
- Author:
Min PANG
;
Guohua REN
;
Yahong SUN
;
Weina HE
;
Yuji AN
;
Jangze XIN
;
Weihua ZHANG
;
Pengyuan SONG
;
Lijun SHENG
- Publication Type:Journal Article
- Keywords:
Digestive system neoplasms;
Nimotuzumab;
Antineoplastic combined chemotherapy protocols
- From:
Cancer Research and Clinic
2012;24(7):454-456
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the efficacy and toxicity of nimotuzumab plus chemotherapy in the treatment of metastatic gastrointestinal tumor.MethodsObservationgroup 22 patients with metastatic gastrointestinal tumor with confirmed diagnosis,were treated with nimotuzumab in combination chemotherapy.Nimotuzumab was given 200 mg weekly for at least six weeks. Control group 21 patients with metastatic gastrointestinal tumor with confirmed diagnosis were treated with only chemotherapy.ResultsThe effects of observation group could be observed in 22 patients, the rate of response(RR)was 31.8％ (7/22), and the disease control rate (DCR) was 72.7 ％ (16/22).QOL was improved.The effects of observation group could be observed in 21 patients,RR was 14.3 ％ (3/21),and the disease control rate was 42.8 ％ (19/21).DCR and QOL improvements were statistically significant different between the two groups.(x2=3.939,x2=4.250,P＜0.05).The two groups had no significant difference in RR and toxicity.ConclusionNimotuzumab in combination with chemotherapy is effective and can improve the disease control rate, toxicity, tolerance,quality of life.
